Copenhagen biopharma developing a GIPR antagonist for obesity.
Founders
Jens Holst(Denmark · ♂)— A University of Copenhagen professor renowned for discovering GLP-1, his decades of incretin-biology research and identification of an endogenous GIPR antagonist led him to co-found Antag to develop next-gen obesity therapies.
Mette Rosenkilde(Denmark · ♀)— A University of Copenhagen professor with deep incretin expertise, she co-discovered an endogenous GIPR antagonist with Jens Holst and co-founded Antag to advance a GLP-1 add-on obesity drug.
In the network
Shares the most investors with (number = shared investors):